María Molina Molina has a degree in Medicine and Surgery (1998), a PhD in Biomedicine (2007) and an associate professor (since 2015) at the University of Barcelona. Dr. Molina is also director of the SEPAR Scientific Committee, member of the Scientific Committee of the EPID Registry, and selected chief of the Rare-ILD Group, Assembly 12, of the European Respiratory Society.

Her scientific career has focused on the study of Interstitial Lung Diseases (IPDs), a heterogeneous group of rare diseases that cause progressive scarring in the lungs that ends up resulting in the death of the patient. She has focused her research especially on pulmonary fibrosis, combining basic and clinical research and with a commitment to cross-sectional and transnational research with quickly applicable results in health.

Among the main milestones to be highlighted in the biomedical research carried out by Dr. Molina are the identification of the clinical utility of the telomeric and genetic study in MPI, contributing to consensus documents for its use in clinical practice and the identification of the angiotensin system in lung as a fibrogenic pathway, including ACE-2 dysregulation. Likewise, she has a special global interest in COVID19 and is the promoter of three clinical trials and principal investigator in 21. In addition, she is a reference for preclinical (in vitro) trials of new antifibrotic drugs. She has also directed nine doctoral theses, four of them defended in the last five years.